JIB-04 JHDM Inhibitor VII NSC 693627 JIB04 CAS: 199596-05-9

CAS NO: 199596-05-9
JIB-04 JHDM Inhibitor VII NSC 693627 JIB04
Chemical Name: JIB-04
Molecular Formula: C17H13ClN4
Formula Weight: 308.76
CAS No.: 199596-05-9
Description Review
Description

JIB-04, also known as JHDM inhibitor VII and NSC 693627, is a small molecule that belongs to the family of histone demethylase inhibitors. It has been identified through high-throughput screening as a potent inhibitor of Jumonji domain-containing protein histone demethylases (JHDMs) and has shown promising anti-cancer activity in preclinical studies.

Chemical Name:

4-(N-(1,3-Dimethyl-2-butynyl)-N-hydroxycarbamoyl)benzoic acid

Molecular Formula:

C14H15NO4

Formula Weight:

261.28 g/mol

CAS No:

199596-05-9

Top Ten Keywords from Google and Synonyms:

  1. JIB-04
  2. JHDM inhibitor VII
  3. NSC 693627
  4. Histone demethylase inhibitor
  5. Anti-cancer activity
  6. Jumonji domain-containing protein
  7. Epigenetic modifier
  8. Gene expression regulation
  9. Chromatin remodeling
  10. Transcriptional control

Synonyms:

  • 4-(N-(1,3-Dimethyl-2-butynyl)-N-hydroxy-carbamoyl)-benzoic acid
  • Benzoic acid, 4-[(1,3-dimethyl-2-butynyl)hydroxyamino]-
  • NSC693627
  • JHDM Inhibitor VII

Health Benefits of JIB-04:

JIB-04 has shown promise as an anti-cancer agent by inhibiting the activity of JHDMs, which are enzymes involved in the modification of histones, a crucial process for gene expression regulation. JIB-04 can induce cell cycle arrest, apoptosis, and inhibition of tumor growth through its epigenetic modifying properties. JIB-04 has also been studied in other diseases such as asthma and inflammation, where it can act as an immunomodulator.

Potential Effects:

JIB-04 has shown potent inhibition of JHDMs, leading to changes in chromatin structure, gene expression regulation, and transcriptional control. By altering the epigenetic landscape of cancer cells, JIB-04 can induce tumor cell death and inhibit tumor growth. JIB-04 has also been shown to regulate the immune response by modulating the activity of T cells, suggesting potential applications in autoimmune disease therapy.

Product Mechanism:

JIB-04 works by inhibiting the activity of JHDMs, which are enzymes involved in the removal of methyl groups from histone proteins. Histones are essential components of chromatin, and their state of modification plays a critical role in the regulation of gene expression. By blocking JHDMs, JIB-04 increases histone methylation levels, thereby altering the epigenetic landscape of cells and affecting gene expression. This leads to transcriptional dysregulation and cell death in cancer cells.

Safety:

JIB-04 has not yet been tested in humans, and safety data are limited to animal studies. In preclinical studies, JIB-04 has shown low toxicity in mice and rats when administered at therapeutic doses. However, like any other drug, JIB-04 may have side effects that need to be studied further in clinical trials.

Side Effects:

The side effects of JIB-04 are currently unknown due to the lack of clinical data. However, JIB-04's mechanism of action suggests that it may cause chromatin remodeling and gene expression dysregulation, leading to adverse effects. Like any other drug, JIB-04 may have off-target effects that need to be evaluated in clinical studies.

Dosing Information:

The optimal dosing of JIB-04 has not been established, and this needs to be determined in clinical trials. In preclinical studies, doses up to 50 mg/kg have been used in mice without significant toxicity. However, the effective dose range in humans may differ, and individual variation in drug metabolism and clearance may affect dosing.

Conclusion:

JIB-04 is a promising small molecule that has shown potent inhibition of JHDMs, leading to changes in chromatin structure and gene expression regulation. JIB-04 has shown promise as an anti-cancer agent and has demonstrated low toxicity in preclinical studies. However, further studies are needed to evaluate its safety and efficacy in humans. JIB-04's potential applications in other diseases such as asthma and inflammation warrant further investigation, and its use as an immunomodulator may provide new therapeutic options for autoimmune diseases. Overall, JIB-04 holds great promise as a novel epigenetic modifier with potential implications for cancer therapy and other diseases involving epigenetic dysregulation

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code